A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

New studies on respiratory syncytial virus (RSV) in both adults and young children show that infections are linked to a ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Hospitalized older adults show low awareness of respiratory syncytial virus (RSV) and their eligibility for vaccination. Among 6,746 adults aged 60 or older, only 10.4% were vaccinated against RSV.

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

Seventy-eight percent of unvaccinated adults are unsure if they were eligible for vaccination or thought they were not.